Curated trials, papers and news. The community helps validate claims — mark items as trustworthy or flag them for discussion. Always read the original source and talk to your care team.
The European Commission approved tofersen under exceptional circumstances for adults with ALS associated with a SOD1 mutation — the first EU therapy targeting a genetic cause of ALS.
After the PHOENIX Phase 3 trial failed to meet its endpoints, the manufacturer voluntarily pulled Relyvrio. Existing US/Canada patients were offered a free drug program.
A summary of why edaravone (Radicava/Radicut) is approved in the US, Japan, Canada and elsewhere but not in Europe, and what that means for patients considering access abroad.
A plain-language overview of riluzole, edaravone and tofersen: how they work, who they're for, and realistic expectations for each.
A live, filterable registry of recruiting ALS trials worldwide. Use filters for location, phase, and eligibility, and discuss any candidate with your care team.
Review of pharmacological, gene, and stem-cell strategies in development for ALS, with notes on which mechanisms are furthest along.